Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Do high levels of CA 19-9 in women with mature cystic teratomas of the ovary warrant further evaluation?
M. G. Ugur1,*, E. Ozturk1, O. Balat1, E. Dikensoy1, S. Teke1, A. Aydin2
1 Department of Obstetrics and Gynecology
2 Department of Pathology, Gaziantep University, Faculty of Medicine, Gaziantep (Turkey)
Eur. J. Gynaecol. Oncol. 2012, 33(2), 207–210;
Published: 10 April 2012
Purpose: To evaluate the serum levels of tumor markers (particularly CA 19-9) in patients with ovarian mature cystic teratomas (MCT) with respect to age, size, bilaterality, menopause, presence of adhesions, complications and the postoperative levels. Methods: We evaluated clinical characteristics and tumor markers of 157 patients with MCT of the ovary operated at our clinic. Results: CA19- 9 was the only tumor marker with a mean serum level (46.95 ± 101.11 U/mL) above the cut-off value and the elevated rate was 33.1%. Tumor size, presence of adhesions and CA 125 levels were significantly higher in patients with elevated CA 19-9. Bilaterality rate was 10.8%. The most common complication was torsion (6.4%). Conclusion: We suggest that elevated levels of CA 19-9 may be expected in MCTs of the ovary and that they will probably be decreased postoperatively. Therefore, postponing evaluation of other possible sources of CA 19-9 elevation in asymptomatic and young patients is more common sense.
Mature cystic teratoma